´ëÇÑÁ¾¾ç³»°úÇÐȸ (¿Â¶óÀÎ)7/8 ºÐ±âÁý´ãȸ : 2021-07-08±³À°ÀÏÀÚ : 2021-07-08
±³À°Àå¼Ò : ¿Â¶óÀÎ ±³À°
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ)7/8 ºÐ±âÁý´ãȸÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ´ëÇÑÁ¾¾ç³»°úÇÐȸ »ç¹«±¹
¿¬¶ôó : 02-735-2857
À̸ÞÀÏ :
ksmo3@ksmo.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07-08 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 18:00~18:40 Novel approaches in 1st line treatment; Adding IO to anti-HER-2 therapy in GC Á¤¹Î±Ô(¿¬¼¼¾Ïº´¿ø)
±³À°½Ã°£ 07-08 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 18:40~19:20 Potential role of her-2 inhibition beyond progression of trastuzumab ±¸µ¿È¸(°ºÏ»ï¼ºº´¿ø)
±³À°½Ã°£ 07-08 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 19:20~20:00 CAR T-cell therapy for B-cell lymphomas ±è¼®Áø(»ï¼º¼¿ïº´¿ø)
±³À°½Ã°£ 07-08 ºñ¾ØµðÆÄÆ®³Ê½º(¼¿ï¿ª½ºÆ©µð¿À) 20:00~21:00 Bispecific T-cell engaging antibody for B-cell lymphomas ±èŹÎ(¼¿ï´ëÇб³º´¿ø)